Many patients with lung adenocarcinoma (LUAD), a major subtype of lung cancer2, harbor mutations in the epidermal growth factor receptor (EGFR) in their cancer tissues and initially react well to molecular targeted drugs such as gefitinib, which inhibits the EGFR-tyrosine kinase3,4. The gene discussed is EGFR; the disease is cancer.